HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 291/1/F196    most recent 00431.2005v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Foster, R. R. Articles by Harper, S. J. Search for Related Content PubMed PubMed Citation Articles by Foster, R. R. Articles by Harper, S. J.

VEGF-C promotes survival in podocytes

¹Microvascular Research Laboratories, Department of Physiology, and ²Academic Renal Unit, Southmead Hospital, University of Bristol, Bristol, United Kingdom; and ³Department of Nephrology, First Affiliated Hospital, Nanjing Medical University, Nanjing, People's Republic of China

Submitted 27 October 2005 ; accepted in final form 9 February 2006

Vascular endothelial growth factor (VEGF)-A is an autocrine survival factor for podocytes, which express two VEGF receptors, VEGF-R1 and VEGF-R3. As VEGF-A is not a known ligand for VEGF-R3, the aim of this investigation was to examine whether VEGF-C, a known ligand for VEGF-R3, served a function in podocyte biology and whether this was VEGF-R3 dependent. VEGF-C protein expression was localized to podocytes in contrast to VEGF-D, which was expressed in parietal epithelial cells. Intracellular calcium ([Ca²⁺]_i) experiments demonstrated that VEGF-C induced a 0.74 ± 0.09-fold reduction in [Ca²⁺]_i compared with baseline in human conditionally immortalized podocytes (hCIPs; P < 0.05, one sample t-test, n = 8). Cytotoxicity experiments revealed that in hCIPs VEGF-C reduced cytotoxicity to 81.4 ± 1.9% of serum-starved conditions (P < 0.001, paired t-test, n = 16), similar to VEGF-A (82.8 ± 4.5% of serum-starved conditions, P < 0.05, paired t-test). MAZ51 (a VEGF-R3 kinase inhibitor) inhibited the VEGF-C-induced reduction in cytotoxicity (106.2 ± 2.1% of serum-starved conditions), whereas MAZ51 by itself had no cytotoxic effects on hCIPs. VEGF-C was also shown to induce a 0.5 ± 0.13-fold reduction in levels of MAPK phosphorylation compared with VEGF-A and VEGF-A-Mab treatment (P < 0.05, ANOVA, n = 4), yet had no effect on Akt phosphorylation. Surprisingly, immunoprecipitation studies detected no VEGF-C-induced autophosphorylation of VEGF-R3 in hCIPs but did so in HMVECs. Moreover, SU-5416, a tyrosine kinase inhibitor, blocked the VEGF-C-induced reduction in cytotoxicity (106 ± 2.8% of serum-starved conditions) at concentrations specific for VEGF-R1. Together, these results suggest for the first time that VEGF-C acts in an autocrine manner in cultured podocytes to promote survival, although the receptor or receptor complex activated has yet to be elucidated.

intracellular calcium; cytotoxicity; lymphatic endothelial cells

This article has been cited by other articles:

				E. Letavernier, P. Bruneval, S. Vandermeersch, J. Perez, C. Mandet, M.-F. Belair, J.-p. Haymann, C. Legendre, and L. Baud Sirolimus interacts with pathways essential for podocyte integrity Nephrol. Dial. Transplant., October 16, 2008; (2008) gfn574v1. [Abstract] [Full Text] [PDF]